Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity:

The Associate Director, Market Access HTA, Spain is responsible for defining and executing the market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. Working closely with the Senior Director, Market Access HTA, in Spain, this role helps to shape business strategies, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities, both at national and regional level

The incumbent will partner with regional and global commercial, HEOR, and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing & Reimbursment dossiers and tools, engaging with market access and public affairs stakeholders as well as participating in pricing strategy activities, and drive the activities to deliver access results supporting the overall success of the product launches.

Responsibilities:

Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for oncology products within the Spanish healthcare system
HTA & Pricing Filings: Lead preparation and submission of value dossiers, and pricing negotiations with MoH and regional HTAs
Value Communication: Translate clinical and economic evidence into compelling value communications tailored for Spanish payers.
External Stakeholder Engagement: Build and maintain strong relationships with key external stakeholders (regional payers and policy maker authorities)
- Identify and prioritize key stakeholders focus on HE with influence in HTAs process.
- Effectively engages with HTA bodies and stakeholders like Regional HTAs, Physicians, Pharmacist and others identify as relevant.
Cross-Functional Collaboration: Work with Global and EU Region Market Access teams to align local access strategy with broader European and corporate objectives, especially in terms of aligning the European regulatory and JCA strategy and execution with local value dossier submission and pricing negotiation strategies
Participation in negotiations with all levels of national and regional payers
Collaborate with internal functions to develop innovative pricing and value based contracting models to optimize the acceleration of reimbursement approvals
Policy Monitoring: Monitor health policy developments, HTA processes and local reimbursement environments to inform strategy
Drive access and value related projects such as landscape assessments, payer market research, payer advidory boards and general guidance on local strategies
Development of outreach and engagement plan for key payers and their influencers creating and maintaining a strong network
Participate in early access planning of new products and indications, drive launch readiness for multiple oncology assets
Market Access in Field base Support:
- Maintain an up-to-date understanding of customer perspectives through regular engagement with payers (e.g. in-field visits).
- Provide in field market access team with materials, strategies and tactics aligned with Strategic Objectives of the Brand & Value and Market Access.
- Continuous up-date on brand strategies and tactics that could impact in the time and conditions to access to the market all Oncology products.

Participate in the elaboration and execution Value and Market Access Strategic and Tactical Plan aligned with Brand Team and field team: access, sales and marketing and medical affairs
Play an active role in the Brand Team, providing input for the HEOR & Pricing Manager and field access team and identify opportunities to work collaboratively with cross-functional colleagues to deliver on brand objectives and provide training of analysis, tools, evidence, actions and programs to support and communicate the value proposition.
Complies with all laws, regulations and policies that govern the conduct of Revolution Medicines staff.
Visibly embodies corporate Core Values while cultivating an energized team culture focused on patient impact

Required Skills, Experience and Education:

Advanced degree (e.g., PhD in Life Sciences, Pharmacy, Health Economics, Public Health)
10+ years experience in market access, pricing, reimbursement or health economics (pharma/biotech/market access consulting)
Experience of involvement in HTA submissions with at least 1 recent HTA submission (within last 12 months). In-depth HEOR technical expertise and experience
Demonstrated success and experience supporting a oncology product pre-launch, launch and post launch in Spain
Demonstrated succces in negotiating pricing and reimbursement conditions with public administrations and health authorities
Strong stakeholder management and ability to collaborate with internal and external partners
Excellent communication skills, both in person and virtual
Scientific and solution-orientated mindset and capability to move and execute in a rapidly changing, ambiguous environment
Strong understanding of local healthcare systems, customer dynamics, and reimbursement environments
Strong commercial and strategic acumen
Willingness to travel nationally and internationally
Proven leadership and people management capabilities; demonstrated success in small but fast growing, entrepreneurial commercial environment

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].

#LI-JM1 #LI-Remote

We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.

Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.

If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.

About the company

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Revolution Medicines

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA approved RASONQUE on August 26, 2026, six months ahead of deadline.
RASolute 302 cut death risk 60% and doubled median overall survival to 13.2 months.
Royalty Pharma's June 2025 $2 billion package funds commercialization and global expansion through 2027.

What critics are saying

RASONQUE costs $39,800 monthly, inviting Medicare and commercial payer restrictions in 2026.
Revenue still depends overwhelmingly on one launch; any RASONQUE setback crushes the company.
AstraZeneca, Amgen, and Mirati pressure RAS programs; resistance or safety issues can erase the franchise.

What makes Revolution Medicines unique

RASONQUE became the first approved broad RAS(ON) inhibitor on August 26, 2026.
Revolution Medicines avoids companion diagnostics and treats metastatic PDAC with or without RAS mutations.
Its pipeline spans daraxonrasib, elironrasib, and zoldonrasib across pancreatic, lung, and colorectal cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

6 month growth

1 year growth

-1%

2 year growth

-1%

Asianet News

Oct 16th, 2026

VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes.

VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes. Published: Oct 16 2026, 03:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us * Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating. * RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. * BTIG said VS-7375 could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company's experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma. On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effects. Verastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end. Wall street weighs in on VSTM. Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class. RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class. CEO change and Capital raising. Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15. The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him. How did VSTM retail traders react? On Stocktwits, retail sentiment around VSTM stayed within 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels. "The more I watch it, the more constructive it looks," a Stocktwits user wrote about the stock. View this Stocktwits post Another user drew a parallel between VSTM's current rally and Iovance Biotherapeutics Inc (IOVA) stock's rally last month, which lasted for several days. View this Stocktwits post VSTM stock has gained 2o% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

pharmaphorum

Oct 16th, 2026

RevMed nears EU okay for pancreatic cancer drug Rasonque.

RevMed nears EU okay for pancreatic cancer drug Rasonque. Revolution Medicines is likely just weeks away from getting EU approval for its oral RAS inhibitor Rasonque as a treatment for pancreatic cancer, after the drug was recommended by the EMA's human medicines committee. The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one previous treatment - the same indication that was cleared by the US FDA in August. The positive opinion is based on phase 3 results with Rasonque from the RASolute 302 trial that caused a stir at this year's ASCO cancer congress, with a doubling in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy and big improvements in quality-of-life scores. The outcome was remarkable, particularly as metastatic pancreatic adenocarcinoma is a notoriously difficult-to-treat cancer with a low survival rate. "People with metastatic pancreatic adenocarcinoma whose disease has worsened after prior treatment have limited treatment options and a poor prognosis," said the EMA, which granted Rasonque an expedited, phased review - which cut its assessment time from 210 days to less than 150 days - as a high-priority medicine that could address this unmet medical need. "Given the seriousness of the disease, [and] the limited efficacy and substantial toxicity of standard-of-care chemotherapy, there is a need for better treatment options for these patients." The RAS protein is a key driver for many tumour types, including the majority of pancreatic cancers. For many years, it was considered an 'undruggable' target, until RevMed solved the problem with daraxonrasib, constructed by binding RAS to a protein called cyclophilin A to form a complex that can attach to the RAS protein and block its activity. The pan-RAS category is pretty crowded, with more than a dozen drug candidates in clinical testing, but Revolution seems to have a healthy first-mover advantage with other trials underway in pancreatic adenocarcinoma, as well as non-small cell lung cancer (NSCLC). Those include the RASolute 303 trial in first-line pancreatic cancer, RASolute 304 in adjuvant treatment of tumours treatable with surgery, and RASolve 301 looking at first-, second-, and third-line treatment of metastatic NSCLC. There has been some noise about Rasonque's slightly lower tumour response rate in patients with KRAS G12D mutations in RASolute 302, which analysts have suggested could open the door to competition from selective drugs like Verastem Oncology's VS-7375, which is in phase 3 for pancreatic cancer. RevMed is, however, also developing a KRAS G12D-selective inhibitor, zoldonrasib, both as a monotherapy and in combination with Rasonque. 16 October, 2026

Yahoo Finance

Oct 15th, 2026

Revolution Medicines and Oruka double in 2026, beating Magnificent Seven; analysts see up to 95% upside

Two biotech stocks, Revolution Medicines and Oruka Therapeutics, have more than doubled this year, beating most of the Magnificent Seven tech group. Wall Street's average price targets suggest further gains. Revolution Medicines won approval for Rasonque, a treatment for certain patients with metastatic pancreatic cancer. In a Phase 3 study, patients lived a median 13.2 months, against 6.7 months on chemotherapy. Its market cap is about $41 billion, and its average price target of $259.14 implies 35.7% upside. Oruka Therapeutics has no approved drug. Its psoriasis candidate, ORKA-001, could be dosed once or twice a year, and has shown strong results in a Phase 2a study. The average price target of $155 implies 95% upside, but the drug has not entered Phase 3 trials.

Yahoo Finance

Oct 15th, 2026

EU regulator backs Revolution Medicines' RASONQUE for pancreatic cancer after 60% lower death risk

Revolution Medicines (Nasdaq: RVMD) said the European Medicines Agency's Committee for Medicinal Products for Human Use has backed RASONQUE (daraxonrasib), an oral tablet for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy. If the European Commission approves it, RASONQUE would be the first broad RAS-targeted treatment option in the European Union for these patients. The opinion followed an expedited review under the agency's Cancer Medicines Pathfinder project. In the Phase 3 RASolute 302 trial, the drug cut the risk of death by 60% compared with chemotherapy. Median overall survival was 13.2 months, against 6.7 months for chemotherapy. The US Food and Drug Administration approved the drug on August 26, 2026.

PR Newswire

Oct 14th, 2026

Cancer drug spending to top $400B by 2028 as RAS-targeted therapies reach pancreatic, colorectal cancers

Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute. The US accounts for roughly 46% of the total. On August 26, the US Food and Drug Administration (FDA) approved Revolution Medicines' RASONQUE (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer. In a Phase 3 trial, median overall survival was 13.2 months, against 6.7 months with chemotherapy. Colorectal cancer is also drawing attention. Oncolytics Biotech expects interim data from Part A of its REO 033 study of pelareorep by year-end. Exelixis saw the FDA extend its review of zanzalintinib for metastatic colorectal cancer to March 3, 2027.

Revolution Medicines

Associate Director, Market Access HTA

About the job